Locally Advanced Rectal Cancer—Precision Therapy in a Time of Moving Targets and Competing Goals
Menée à partir de données portant sur 1 232 patients atteints d’un cancer rectal de stade localement avancé et inclus dans un essai de phase II, cette étude analyse l’association entre l’adhésion aux traitements (chimioradiothérapie néoadjuvante et chimiothérapie adjuvante) et la survie sans maladie
In this issue of JAMA Oncology, Diefenhardt and colleagues1 report a post hoc analysis of the previously published German CAO/ARO/AIO-04 trial and found that the ability of patients with rectal cancer to complete planned neoadjuvant (but not adjuvant) therapy was associated with improved disease-free survival. The authors concluded “the findings emphasize the need for appropriate trial design with optimized nCRT [neoadjuvant chemoradiotherapy] dose and schedule and supportive strategies to facilitate good adherence and precision delivery, especially for intensified nCRT. Few would dispute this broad point, but the greater challenge lies in aligning their recommendations with current paradigms of rectal cancer treatment, which have evolved dynamically since the CAO/ARO/AIO-04 study.
JAMA Oncology , commentaire, 2019